PolyTherics Receives Second Patent Allowance in Record Time
Advertisement
PolyTherics Limited announced that a second patent has been allowed covering the targeted PEGylation of proteins. Issued by the United States Patent Office, this allowance protects PolyTherics’ PEGylation technology in the two largest pharmaceutical markets in the world. This news comes two weeks after the allowance of the first patent within Europe.
The patent claims the use of a unique linker developed at PolyTherics that enables precision attachment of PEG to natural disulfide bonds in proteins. Trademarked as TheraPEG™, the technology allows proteins with proven therapeutic efficacy such as Interferons, erythropoietin and antibody fragments to remain active and potent in the body for longer, resulting in less frequent dosing without loss of biological activity. TheraPEG™ has been shown to be a highly efficient, reliable and cost effective process which complements the proven cost benefits of bacterial expression to produce therapeutic proteins.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Artificial intelligence helps to find new natural substances - New method enables fast and confident identification of previously unknown small molecules
Eckert & Ziegler subsidiary IBt Bebig acquires specialist for medical planning software
Syngenta invests in Avidex
Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type - Triggers US$ 9.0 m payment to Evotec
Immune Cells Also Attack Neurons Directly - New Findings on Multiple Sclerosis
Instant messaging in proteins discovered - Researchers unravel fundamental communication processes in proteins
Australian_and_New_Zealand_College_of_Anaesthetists
Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
Symphogen: Patent for Polyclonal Antibody Compositions for Allergy Treatment